Dr. oec. troph. Johanna Breilmann

MSc in nutritional science
Research assistant

Phone: +49 8221 96-29209
Fax: +49 8221 96-28172

E-Mail: johanna.breilmann@uni-ulm.de

Johanna Breilmann is a research assistant at the Department of Psychiatry II of the Ulm University. She is the project coordinator of the “IMPPETUS” and “EPPIK” projects, which are funded by Innovation Committee of the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), Germany. Furthermore, she works on systematic reviews and meta-analyses on psychiatric and nutritional psychiatric topics, including international Cochrane reviews.
Previously, Johanna Breilmann worked and received her PhD degree at the Institute of Nutrition Science at the University of Giessen, Germany, where she was involved in the organization, implementation and data analysis of a prospective cohort study, in which the nutritional and health status of community-dwelling senior citizens in Giessen, Germany (GISELA study) were investigated.

Projects

EPPIK - Verification of the suitability of the "platform model" as an instrument for personnel allocation in psychiatric and psychosomatic clinics

IMPPETUS - Implementation of the patient guideline psychosocial interventions for patients with severe mental disorders

Systematic Reviews / Meta-Analysen:

  1. Efficacy of Vortioxetine and Benzodiazepines
  2. Dose-response-relationship in cognitive behavioral therapies
  3. Nutritional interventions for people with severe mental disorders in Germany

Nutrition of people with mental disorders

since 2016Research assistant at the Department of Psychiatry II, Ulm University
2008 - 2016Research assistant, Justus-Liebig-Universität Gießen, Institute of Nutritional Sciences
2014Dr. oec. troph., Justus-Liebig-Universität Gießen
2007M. Sc. in Nutritional Sciences, Justus-Liebig-Universität Gießen
2005B. Sc. in Nutritional Sciences, Justus-Liebig-Universität Gießen

 

Papers
  1. Schneider C, Breilmann J, Reuter B, Becker T, Kösters M: Systematic evaluation of the ‘efficacy-effectiveness gap’ in the treatment of depression with venlafaxine and duloxetine. Acta Psychiatr Scand 2021; Mar 4. doi: 10.1111/acps.13293.
  2. Breilmann J, Kilian R, Riedel-Heller SG, Gühne U, Hasan A, Falkai P, Allgöwer A, Muche R, Becker T, Ajayi K, Brieger P, Frasch K, Heres S, Jäger M, Küthmann A, Putzhammer A, Schmauß M, Schneeweiß B, Schwarz M, Kösters M. Implementation of the patient version of the evidence-based (S3) guideline for psychosocial interventions for patients with severe mental illness (IMPPETUS): study protocol for a cluster randomised controlled trial. Trials 2020; 21(1):275.
  3. Breilmann J, Girlanda F, Guaiana G, Barbui C, Cipriani A, Castellazzi M, Bighelli I, Davies SJC, Furukawa TA, Koesters M: Benzodiazepines versus placebo for panic disorder in adults (Review). Cochrane Database Syst Rev 2019; 3:CD010677.
  4. Breilmann J, Furukawa TA, Becker T, Koesters M. Differences in the placebo response in duloxetine and venlafaxine trials. Acta Psychiatr Scand 2018; 137(6):472-480.
  5. Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C: Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017; 7:CD011520.
  6. Breilmann J, Pons-Kühnemann J, Brunner C, Richter M, Neuhäuser-Berthold M: Effect of antioxidant vitamins on the plasma homocysteine level in a free-living elderly population. Ann Nutr Metab 2010; 57:177-182.
     
  • Acta Psychiatrica Scandinavica
  • Epidemiology and Psychiatric Sciences
  • Social Psychiatry and Psychiatric Epidemiology (SPPE)